<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-927" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part indexed="no" book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Aliskiren (Archived)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jacobs</surname>
            <given-names>Tibb F.</given-names>
          </name>
          <aff>University of Louisiana Monroe</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salisbury</surname>
            <given-names>Blake H.</given-names>
          </name>
          <aff>MSUCHM - Ascension Providence</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Terrell</surname>
            <given-names>Jamie M.</given-names>
          </name>
          <aff>University of LA Monroe</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tibb Jacobs declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Blake Salisbury declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jamie Terrell declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-927.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">
<bold>FDA-Approved Indications</bold>
</p>
        <p>
<bold>Hypertension</bold>
</p>
        <p>Aliskiren is FDA-approved to&#x000a0;treat hypertension in adults and children&#x000a0;6 years and older.&#x000a0;Aliskiren may be used as monotherapy or in combination with other antihypertensive agents.<xref ref-type="bibr" rid="article-927.r1">[1]</xref>&#x000a0;Aliskiren was discontinued by the manufacturer due to risks of hyperkalemia and hypotension. This article is presented as a historical record.</p>
        <p>Aliskiren received approval in 2007 after demonstrating its antihypertensive effects in&#x000a0;6 randomized, double-blind, placebo-controlled trials. All patients included had mild to moderate hypertension. Most patients demonstrated a blood pressure-lowering effect within&#x000a0;2 weeks of treatment. These study results revealed a mean reduction in systolic blood pressure of 2.9 to 10 mm Hg and a mean decrease in diastolic blood pressure of 3.3 to 8.6 mm Hg.<xref ref-type="bibr" rid="article-927.r2">[2]</xref><xref ref-type="bibr" rid="article-927.r3">[3]</xref><xref ref-type="bibr" rid="article-927.r4">[4]</xref></p>
        <p>In November 2017, the American College of Cardiology (ACC) and the American Heart Association (AHA) released updated treatment guidelines for patients with high blood pressure. According to the 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, most patients will have a blood pressure goal of less than 130/80 mm Hg. This guideline is a significant change from the 2014 JNC 8 Guidelines (Evidence-based guideline for managing high blood pressure in adults: a report from panel members appointed to the Eighth Joint National Committee JNC8). The JNC 8 guidelines recommended a blood pressure goal of 140/90 mm Hg for most patients and an even higher&#x000a0;reading&#x000a0;for&#x000a0;older patients. For patients older than 60, the JNC 8 guideline recommended a blood pressure goal of less than 150/90 mm Hg.</p>
        <p><bold>Off-Label Uses</bold>&#x000a0;</p>
        <p>In addition to the new lower blood pressure goals, the ACC/AHA guidelines strongly focus on decreasing the risk of cardiovascular disease. Their current recommendation is that patients with elevated blood pressure should receive treatment with medication to reduce cardiovascular risk by lowering blood pressure. However, aliskiren does not currently&#x000a0;have outcome data demonstrating cardiovascular disease (CVD) risk reduction with its use.&#x000a0;The ACC/AHA guidelines emphasize the importance of blood pressure-lowering over drug selection, but initial recommendations for most patients currently&#x000a0;include calcium channel blockers, thiazide diuretics, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin-receptor blockers (ARB) because of their evidence of CVD risk reduction.</p>
        <p>There is also no outcome data for using aliskiren in patients with diabetes mellitus and nephropathy, patients with coronary artery disease, or post-MI patients. The ATMOSPHERE study found aliskiren not to be inferior to enalapril in congestive heart failure patients in the primary composite endpoint of cardiovascular death or heart failure hospitalization.<xref ref-type="bibr" rid="article-927.r5">[5]</xref><xref ref-type="bibr" rid="article-927.r6">[6]</xref> Aliskiren is not indicated for these conditions and would probably not be a substitute for ACEIs or ARBs for these patients.</p>
        <p>At this time, aliskiren remains a medication that would be most appropriate for use as an add-on therapy for patients already managed with&#x000a0;one or more medications that have demonstrated the ability to decrease cardiovascular risk.<xref ref-type="bibr" rid="article-927.r7">[7]</xref><xref ref-type="bibr" rid="article-927.r8">[8]</xref></p>
        <p>Savoia C. et al conducted a clinical trial on&#x000a0;16 patients with mild essential hypertension and type 2 diabetes.<xref ref-type="bibr" rid="article-927.r9">[9]</xref> The researchers compared the vasorelaxant effects of aliskiren (N = 9) and ramipril (N = 7) from small artery biopsies. The doses used on the patients were 150 mg once daily for aliskiren and 5 mg once daily for ramipril. A micromyograph evaluated the endothelium-mediated vasorelaxant effects of acetylcholine plus or minus N omega-nitro-L-arginine methyl ester HCL in norepinephrine-pretreated vessels. Both aliskiren and ramipril reduced blood pressure. Aliskiren demonstrated statistically improved endothelium-mediated relaxation, increasing the formation of endothelial p1177 nitric oxide synthase. Savoia C. et al concluded that aliskiren caused quicker peripheral vasodilation in mild hypertensive type 2 diabetes patients.</p>
        <p>Bokuda K. et al conducted a study on&#x000a0;39 patients with hypertension and chronic kidney disease.<xref ref-type="bibr" rid="article-927.r10">[10]</xref> The patients received one-time aliskiren or amlodipine treatment. The renin-angiotensin system's vascular, renal, and elements were evaluated before treatment at&#x000a0;12 weeks and again at&#x000a0;24 weeks. The aliskiren cohort significantly reduced the cardio-ankle vascular index, protein excretion, and urinary albumin.&#x000a0;These researchers concluded that aliskiren demonstrated additional renal and vascular protection in addition to its blood pressure-lowering effects.</p>
      </sec>
      <sec id="article-927.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Aliskiren is active in the renin-angiotensin-aldosterone system (RAAS).<xref ref-type="bibr" rid="article-927.r11">[11]</xref> Renin&#x000a0;secretion occurs by specialized cells found in the juxtaglomerular apparatus&#x000a0;within&#x000a0;the kidney based on changes in blood volume and renal perfusion as sensed by the macula densa in the distal tubule of the nephron. Renin is responsible for converting angiotensinogen to angiotensin I. Angiotensin I is then converted to angiotensin II by the angiotensin-converting enzyme (ACE), which is present in the lungs' capillaries and endothelial cells in the kidneys. Angiotensin II is believed to be the first active mediator in the RAAS system and exerts its effects by binding to the AT1 receptor and works as a vasoconstrictor, causing the release of catecholamines and promoting aldosterone secretion and sodium reabsorption. These effects together act to increase blood pressure. Angiotensin II&#x000a0;also&#x000a0;can inhibit renin release, causing negative feedback to the renin-angiotensin-aldosterone system.&#x000a0;</p>
        <p>Aliskiren acts as a renin inhibitor, which blocks the conversion of angiotensinogen to angiotensin I. This effect subsequently decreases the formation of angiotensin II. Angiotensin II acts on the AT1 receptor, responsible for vasoconstriction, aldosterone secretion, and catecholamine release.&#x000a0;Hence, blood pressure decreases by decreasing the amount of angiotensin II that reaches the AT1 receptor, thereby&#x000a0;causing a decrease in vasoconstriction, aldosterone secretion, and catecholamine release. Any agent that works to inhibit the RAAS can suppress the negative feedback loop.</p>
        <p>O'Rawe et al conducted a phase I clinical trial to determine the safety and tolerability of several drugs that target the renin-angiotensin system in patients with glioblastoma.<xref ref-type="bibr" rid="article-927.r12">[12]</xref> The glioblastoma stem cells contain elements of the renin-angiotensin system. Thus, inhibiting the renin-angiotensin system in glioblastoma stem cells might have anticancer effects. Patients who relapsed from standard treatment, eg, surgery, radiation, and temozolomide, and met inclusion criteria received oral doses of aliskiren, aspirin, celecoxib, cilazapril, curcumin/piperine, metformin, and propranolol. Ten patients out of&#x000a0;17 completed the pharmacotherapy regimen. Two patients reported mild adverse effects. The median survival was 19.9 months compared with 14.6 months for standard therapy. O'Rawe et al state that this difference is not statistically significant. However, the trend of greater survival time for relapsed patients receiving drugs that target the renin-angiotensin system is a promising lead.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption</bold>
</p>
        <p>Aliskiren is poorly absorbed in the gastrointestinal tract, with a bioavailability between 2.0 and 2.5%. The drug achieves peak plasma concentrations between 1 and 3 hours following administration, and steady-state concentrations are achieved within 7 to 8 days of starting regular administration.<xref ref-type="bibr" rid="article-927.r13">[13]</xref><xref ref-type="bibr" rid="article-927.r14">[14]</xref></p>
        <p>
<bold>Distribution</bold>
</p>
        <p>Eighty percent of aliskiren in the plasma is unchanged drug, and its volume of distribution at steady-state&#x000a0;is approximately 135 L.<xref ref-type="bibr" rid="article-927.r14">[14]</xref><xref ref-type="bibr" rid="article-927.r15">[15]</xref>&#x000a0;The drug's&#x000a0;average protein binding is 49.5%.</p>
        <p>
<bold>Metabolism</bold>
</p>
        <p>Aliskiren's&#x000a0;major metabolic pathwayis O-demethylation at the phenyl-proxy side chain or the 3-methoxypropoxy group, with further oxidation to the carboxylic acid derivative. Aliskiren is&#x000a0;also&#x000a0;minimally metabolized by CYP3A4 enzymes,&#x000a0;but it is not an inhibitor or inducer of the cytochrome P450 hepatic enzyme system. Aliskiren's&#x000a0;half-life averages 24 hours, making it suitable for once-daily dosing.</p>
        <p>
<bold>Excretion</bold>
</p>
        <p>Aliskiren is partially cleared by the kidneys and excreted in the urine, 25% as an unchanged drug.</p>
      </sec>
      <sec id="article-927.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Dosage Forms and Strengths</bold>
</p>
        <p>Aliskiren is available as 150 mg or 300 mg tablets. Patients usually initiate therapy on 150 mg daily, which may be increased to 300 mg daily&#x000a0;if necessary. Doses over 300 mg daily did not demonstrate any additional blood pressure lowering but did show an increased rate of diarrhea. Aliskiren is also available as oral pellets for patients who cannot swallow tablets. The pellets are available as a 37.5 mg capsule.&#x000a0;Aliskiren is also available in combination with hydrochlorothiazide in multiple strengths: 150-12.5 mg, 150-25 mg, 300-12.5 mg, and 300-25 mg, respectively.&#x000a0;The drug is also&#x000a0;marketed with amlodipine and hydrochlorothiazide: 150-5-12.5 mg, 300-5-12.5 mg, 300-5-25 mg, 300-10-12.5 mg, and 300-10-25 mg, respectively.&#x000a0;A combination formulation with aliskiren and amlodipine was discontinued.<xref ref-type="bibr" rid="article-927.r16">[16]</xref></p>
        <p>Aliskiren administration is via the oral route; it should be taken daily at the same time. Patients may take aliskiren with or without a meal, but the recommendation is for consistent administration with meals. High-fat meals can decrease the absorption of aliskiren.</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>For hypertension: 150 to 300&#x000a0; mg orally once daily. Maximum dose is 300 mg daily.</p>
        <p>
<bold>Pediatric Dosing</bold>
</p>
        <p>For hypertension in children 6 or older:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>20 to 50 kg:</bold> 75 to 150 mg orally daily. The maximum dose is 150 mg daily.</p>
          </list-item>
          <list-item>
            <p><bold>&#x0003e;50 kg:</bold>&#x000a0;150 to 300 mg orally once daily. The maximum dose is 300 mg daily.</p>
          </list-item>
        </list>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <p>No dose adjustment is necessary.</p>
        <p>
<bold>Renal Impairment</bold>
</p>
        <p>For a CrCl &#x0003e;30, there are no dose adjustments. Patients on hemodialysis require no dose adjustment and no supplement. Peritoneal dialysis dosing remains undefined at present.</p>
        <p>
<bold>Pregnant Women</bold>
</p>
        <p>Avoid using aliskiren during pregnancy. If the drug is necessary, monitor amniotic fluid and fetus closely; there is no known risk of teratogenicity, but animal data points towards possible low birth weight.<xref ref-type="bibr" rid="article-927.r17">[17]</xref></p>
        <p>
<bold>Breastfeeding Women</bold>
</p>
        <p>No human data exists to assess infant harm or impact on milk production; clinicians should weigh the risks vs benefits.</p>
        <p>
<bold>Pediatric Patients</bold>
</p>
        <p>See pediatric dosing above.</p>
        <p>
<bold>Older Patients</bold>
</p>
        <p>Study results have&#x000a0;revealed no&#x000a0;problems specific to older patients that would limit the use of&#x000a0;aliskiren in this population. However,&#x000a0;older patients are more sensitive to the effects of&#x000a0;aliskiren.</p>
      </sec>
      <sec id="article-927.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>According to the package insert, the primary adverse effect of aliskiren is diarrhea, with 2.3% of patients experiencing it. Other common adverse effects include a cough, rash, headaches, and dizziness.</p>
        <p>Clinical lab findings&#x000a0;observed in clinical trials include increased blood urea nitrogen or serum creatinine, small decreases in hemoglobin and hematocrit, increases in serum potassium, increased serum uric acid, and increased creatine kinase.<xref ref-type="bibr" rid="article-927.r18">[18]</xref>&#x000a0;Serious adverse reactions reported in clinical trials include&#x000a0;fetal toxicity, anaphylactic reactions, head and neck angioedema, and hypotension.<xref ref-type="bibr" rid="article-927.r19">[19]</xref><xref ref-type="bibr" rid="article-927.r20">[20]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Aliskiren is contraindicated with ACE inhibitors and angiotensin receptor blockers in diabetic patients due to additive effects. Other drugs to avoid include amikacin, aripirazole, cyclosporine, itraconazole, potassium chloride, ritonavir, and tacrolimus. As always, a thorough medication reconciliation is necessary before any drug regimen changes.</p>
      </sec>
      <sec id="article-927.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>According to the manufacturer, aliskiren is contraindicated in patients with a known hypersensitivity to any component, in pediatric patients younger than 2, and in patients with diabetes who take an ACE inhibitor or an angiotensin receptor blocker.&#x000a0;Patients should not use aliskiren in pregnancy or if they are taking an ARB or ACEI. Caution is necessary for patients with volume depletion.</p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Aliskiren carries an FDA Box Warning for fetal toxicity. If pregnancy is detected, aliskiren must be stopped immediately, as drugs that act directly&#x000a0;on the renin-angiotensin system can&#x000a0;result in fetal injury and death.</p>
      </sec>
      <sec id="article-927.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Medical staff should observe patients taking aliskiren for hyperkalemia and impaired renal function. Serum potassium requires periodic monitoring. Patients at risk include those with renal insufficiency, diabetes mellitus, combination use with ARBs or ACEs, and patients using potassium supplements or potassium-sparing diuretics. Renal function&#x000a0;also&#x000a0;should be monitored periodically.&#x000a0;Individual patients will be at higher risk of developing acute renal failure while taking aliskiren. These patients include those taking ARBs, ACEIs, non-steroidal anti-inflammatory drugs (NSAIDs), and patients with renal artery stenosis, severe heart failure, post-myocardial infarction, or volume depletion.<xref ref-type="bibr" rid="article-927.r21">[21]</xref><xref ref-type="bibr" rid="article-927.r22">[22]</xref></p>
      </sec>
      <sec id="article-927.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is limited data regarding overdose in humans. Patients would most likely present with hypotension. If this occurs, supportive treatment would be appropriate.</p>
      </sec>
      <sec id="article-927.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Healthcare workers, including nurse practitioners who prescribe aliskiren for hypertension in adults, should know the contraindications and precautions. Patients taking&#x000a0;aliskiren require monitoring for hyperkalemia and impaired renal function. Serum potassium also requires periodic observation. Patients at risk include those with renal insufficiency, diabetes mellitus, combination use with&#x000a0;ARBs&#x000a0;or ACEs, and patients using potassium supplements or potassium-sparing diuretics. Renal function is also something clinicians should watch.&#x000a0;Individual patients will be at higher risk of developing acute renal failure while taking&#x000a0;aliskiren. These patients include those taking ARBs, ACEIs, non-steroidal&#x000a0;anti-inflammatory&#x000a0;drugs (NSAIDs), and patients with renal artery stenosis, severe heart failure, post-myocardial infarction, or volume depletion.</p>
        <p>As part of a patient's overall hypertensive control regimen, aliskiren therapy requires an interprofessional healthcare team that includes physicians, advanced practice practitioners, nursing staff, and pharmacists. When initiating aliskiren, the clinician should consult a pharmacist, who can review the entire medication regimen and assist with deciding the appropriateness of adding aliskiren and what other changes might be necessary for the patient's regimen. Nursing staff can provide administration counseling, monitor the patient, and assess pharmacotherapy adherence. If the nurse or pharmacist notes any issues, they should be able to communicate these to the prescriber promptly, giving their clinical opinion regarding the patient's condition. With interprofessional team coordination, aliskiren therapy can achieve optimal outcomes with minimal adverse events.&#x000a0;</p>
      </sec>
      <sec id="article-927.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=927&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=927">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/927/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=927">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-927.s10">
        <title>References</title>
        <ref id="article-927.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews.</article-title>
            <source>BMC Cardiovasc Disord</source>
            <year>2020</year>
            <month>Apr</month>
            <day>17</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>179</fpage>
            <pub-id pub-id-type="pmid">32303191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x00141;ukawski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Raszewski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Czuczwar</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Effect of aliskiren, a direct renin inhibitor, on the protective action of antiepileptic drugs against pentylenetetrazole-induced clonic seizures in mice.</article-title>
            <source>Fundam Clin Pharmacol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>191</fpage>
            <page-range>191-198</page-range>
            <pub-id pub-id-type="pmid">30312501</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamashita</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Nabi</surname>
                <given-names>AHMN</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ebihara</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Aliskiren reduces the release of soluble (pro)renin receptor from human umbilical vein endothelial cells.</article-title>
            <source>Biomed Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>247</fpage>
            <page-range>247-252</page-range>
            <pub-id pub-id-type="pmid">30271601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nishiyama</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A novel role of renin inhibitor in the complement cascade.</article-title>
            <source>Kidney Int</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>650</fpage>
            <page-range>650-652</page-range>
            <pub-id pub-id-type="pmid">30243307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bjerre</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Buus</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Simonsen</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The role of aliskiren in the management of hypertension and major cardiovascular outcomes: a systematic review and meta-analysis.</article-title>
            <source>J Hum Hypertens</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>795</fpage>
            <page-range>795-806</page-range>
            <pub-id pub-id-type="pmid">30631130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaduganathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cheema</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cleveland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sankar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Subacius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Maggioni</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zannad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gheorghiade</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.</article-title>
            <source>Eur J Heart Fail</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>677</fpage>
            <page-range>677-686</page-range>
            <pub-id pub-id-type="pmid">29143416</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yandrapalli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jolly</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Biswas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rochlani</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Harikrishnan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Lanier</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Newer hormonal pharmacotherapies for heart failure.</article-title>
            <source>Expert Rev Endocrinol Metab</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-49</page-range>
            <pub-id pub-id-type="pmid">30063443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simeoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nicotera</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pelagi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Libri</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Comi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fuiano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Successful Use of Aliskiren in a Case of IgA- Mesangial Glomerulonephritis Unresponsive to Conventional Therapies.</article-title>
            <source>Rev Recent Clin Trials</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-76</page-range>
            <pub-id pub-id-type="pmid">30047335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savoia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Ciuceis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Paini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carletti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arrabito</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nicoletti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mercantini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Di Gioia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Battistoni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ucci</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agabiti Rosei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Volpe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muiesan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Rizzoni</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salvetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of direct renin inhibition on vascular function after long-term treatment with aliskiren in hypertensive and diabetic patients.</article-title>
            <source>J Hypertens</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>39</volume>
            <issue>1</issue>
            <fpage>169</fpage>
            <page-range>169-180</page-range>
            <pub-id pub-id-type="pmid">32740409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bokuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yatabe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yatabe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ando</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Itoh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ichihara</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Greater reductions in plasma aldosterone with aliskiren in hypertensive patients with higher soluble (Pro)renin receptor level.</article-title>
            <source>Hypertens Res</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>435</fpage>
            <page-range>435-443</page-range>
            <pub-id pub-id-type="pmid">29618841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pantzaris</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Karanikolas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsiotsios</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Velissaris</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Renin Inhibition with Aliskiren: A Decade of Clinical Experience.</article-title>
            <source>J Clin Med</source>
            <year>2017</year>
            <month>Jun</month>
            <day>09</day>
            <volume>6</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">28598381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Rawe</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wickremesekera</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>FitzJohn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>ST</given-names>
              </name>
            </person-group>
            <article-title>Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial.</article-title>
            <source>J Clin Neurosci</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>95</volume>
            <fpage>48</fpage>
            <page-range>48-54</page-range>
            <pub-id pub-id-type="pmid">34929651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buczko</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hermanowicz</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of aliskiren, an oral direct renin inhibitor.</article-title>
            <source>Pharmacol Rep</source>
            <year>2008</year>
            <season>Sep-Oct</season>
            <volume>60</volume>
            <issue>5</issue>
            <fpage>623</fpage>
            <page-range>623-31</page-range>
            <pub-id pub-id-type="pmid">19066408</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaidyanathan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jarugula</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dieterich</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dole</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and pharmacodynamics of aliskiren.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2008</year>
            <volume>47</volume>
            <issue>8</issue>
            <fpage>515</fpage>
            <page-range>515-31</page-range>
            <pub-id pub-id-type="pmid">18611061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldmeier</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Glaenzel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Wirz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Oberer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seiberling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Valencia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Riviere</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>End</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vaidyanathan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1418</fpage>
            <page-range>1418-28</page-range>
            <pub-id pub-id-type="pmid">17510248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <article-title>Aliskiren/amlodipine (Tekamlo): another combination tablet for hypertension.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2010</year>
            <month>Nov</month>
            <day>29</day>
            <volume>52</volume>
            <issue>1352</issue>
            <fpage>94</fpage>
            <page-range>94-5</page-range>
            <pub-id pub-id-type="pmid">21116232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for hypertension.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2020</year>
            <month>May</month>
            <day>18</day>
            <volume>62</volume>
            <issue>1598</issue>
            <fpage>73</fpage>
            <page-range>73-80</page-range>
            <pub-id pub-id-type="pmid">32555118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Roddick</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Ayis</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients.</article-title>
            <source>Diab Vasc Dis Res</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>400</fpage>
            <page-range>400-406</page-range>
            <pub-id pub-id-type="pmid">28844155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schlienger</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Korn</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Wehler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lopez Leon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yeaw</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Angioedema Among Hypertensive Patients Treated with Aliskiren or Other Antihypertensive Medications in the United States.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>465</fpage>
            <page-range>465-474</page-range>
            <pub-id pub-id-type="pmid">28779444</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takamiya</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shirai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Urata</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez&#x000ae; (CHAT-Ras).</article-title>
            <source>Clin Exp Hypertens</source>
            <year>2020</year>
            <month>Aug</month>
            <day>17</day>
            <volume>42</volume>
            <issue>6</issue>
            <fpage>545</fpage>
            <page-range>545-552</page-range>
            <pub-id pub-id-type="pmid">32037898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>B&#x000e9;k&#x000e1;ssy</surname>
                <given-names>ZD</given-names>
              </name>
              <name>
                <surname>Kristoffersson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rebetz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tati</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Olin</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Karpman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Aliskiren inhibits renin-mediated complement&#x000a0;activation.</article-title>
            <source>Kidney Int</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>94</volume>
            <issue>4</issue>
            <fpage>689</fpage>
            <page-range>689-700</page-range>
            <pub-id pub-id-type="pmid">29884545</pub-id>
          </element-citation>
        </ref>
        <ref id="article-927.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pawloski</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Horinouchi</surname>
                <given-names>CDS</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Olchanheski</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Machado</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cabrini</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Dietrich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paludo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Otuki</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Aliskiren: Preclinical evidence for the treatment of hyperproliferative skin disorders.</article-title>
            <source>Biomed Pharmacother</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>104</volume>
            <fpage>151</fpage>
            <page-range>151-157</page-range>
            <pub-id pub-id-type="pmid">29772435</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
